PTH and osteoporosis: In a recent single-center, nonrandomized observational study, researchers evaluated the efficacy and safety of 1-year romosozumab administration (210 mg monthly), in 76 hemodialysis patients with osteoporosis, high risk of fracture, and PTH levels of 152.3 ± 172.0 pg/mL (399).